STOCK TITAN

Cardio Diagnostics Holdings Inc - CDIO STOCK NEWS

Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.

Cardio Diagnostics Holdings Inc (CDIO) delivers AI-powered innovations in cardiovascular risk assessment through its proprietary Genetic-Epigenetic Engine. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's advancements in precision diagnostics.

Access timely announcements about clinical validations, strategic partnerships, and regulatory developments shaping the future of preventive cardiovascular care. Our curated collection includes earnings reports, technology milestones, and peer-reviewed research insights directly impacting CDIO's market position.

Key updates cover advancements in AI-driven diagnostic accuracy, intellectual property expansions, and collaborations with medical institutions. Users gain critical insights into how CDIO's epigenetic analyses are transforming personalized healthcare approaches globally.

Bookmark this page for structured access to verified corporate communications and analysis of CDIO's growing influence in biotechnology. Regularly updated content supports informed tracking of the company's progress in redefining cardiovascular disease prevention through cutting-edge diagnostic solutions.

Rhea-AI Summary
Cardio Diagnostics Holdings, a pioneering AI-driven precision cardiovascular medicine company, announced that India’s Patent Office has granted a patent to the University of Iowa Research Foundation under patent number 484488. The patent was exclusively licensed to the Company from the University of Iowa Research Foundation and co-invented by Cardio Diagnostics’ founders, Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D. The Company’s global patent portfolio includes granted patents in the United States, Europe, India, Australia, China, and Hong Kong, and numerous pending patents worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.13%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings, an AI-driven precision cardiovascular medicine company (Nasdaq: CDIO), introduces HeartRisk to help employers understand and mitigate cardiovascular risks in their workforce. HeartRisk provides actionable insights related to cardiovascular disease, such as the amount of stop-loss insurance to carry based on the degree of CVD risk in the relevant population or selections of appropriate chronic care management partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
Rhea-AI Summary
CARDIO DIAGNOSTICS HOLDINGS, INC. (Nasdaq: CDIO) introduces HeartRisk™, an employer cardiovascular disease risk intelligence platform to combat cardiovascular disease in the workforce and mitigate business risks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
Rhea-AI Summary
Cardio Diagnostics Holdings, an AI-driven precision cardiovascular medicine company (Nasdaq: CDIO), has received a dedicated CPT PLA code, 0439U, from the American Medical Association for its AI-powered coronary heart disease event risk assessment test, Epi+Gen CHD. This milestone will accelerate reimbursement from federal and private payers, increasing access to precision cardiovascular medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
AI
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has achieved a milestone by obtaining a dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA) code, 0440U, from the American Medical Association (AMA) for its AI-driven coronary heart disease (CHD) detection test, PrecisionCHD. This will facilitate reimbursement from federal and private payers and expand access to the innovative test. The CPT PLA code will be effective on April 1, 2024, and is a significant step toward broader adoption of the first and only integrated genetic-epigenetic diagnostic blood test for CHD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.89%
Tags
AI
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) appoints Paul Burton, J.D., MBA as Independent Director, bringing over 20 years of experience in medical technology innovation, corporate finance, and shaping the strategy and operations of growth-stage companies. Mr. Burton will Chair the Nominating and Corporate Governance Committee and serve as a member of the Audit Committee. His expertise in healthcare investing, growth strategy, and FDA navigation will be invaluable in advancing Cardio Diagnostics' vision of using advanced diagnostics for more personalized cardiovascular care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
management
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has regained compliance with the minimum bid price requirement set forth by Nasdaq, ensuring continued listing on The Nasdaq Capital Market. The company's common stock maintained a minimum closing bid price of $1.00 or more for 10 consecutive business days, from November 20, 2023, to December 4, 2023, leading to Nasdaq closing the matter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings, a leader in artificial intelligence-driven precision cardiovascular medicine tests, will be attending the 42nd Annual J.P. Morgan Healthcare Conference from January 8 to 11, 2024, in San Francisco, CA. The company's management will be presenting a roundtable session titled 'Operationalizing Value-Based Care in Shared Risk Contracts: A Novel Model for Heart Disease Risk Management' to discuss risk mitigation strategies across the cardiovascular medicine continuum. The roundtable will bring together healthcare stakeholders to discuss operationalizing value-based care with novel risk-stratification strategies in the cardiovascular disease space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is convening a roundtable at the 42nd Annual J.P. Morgan Healthcare Conference to discuss operationalizing value-based care with novel risk-stratification strategies in the cardiovascular disease space. The company's management will be attending the conference from January 8 to 11, 2024, in San Francisco, CA. The roundtable will bring together healthcare stakeholders to facilitate the development of more robust value-based care models for tackling heart disease risks to support better patient outcomes and innovative payer models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
none
Rhea-AI Summary
Cardio Diagnostics Holdings, a leader in AI-driven precision cardiovascular medicine tests, announced that the AMA is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT PLA codes. If approved, the codes are expected to be published by January 1, 2024, and will be effective on April 1, 2024. This move would be a significant step towards securing federal and private payer reimbursement for the tests, streamlining the reimbursement process and facilitating broader adoption of Cardio's next-generation cardiovascular tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
none
Cardio Diagnostics Holdings Inc

Nasdaq:CDIO

CDIO Rankings

CDIO Stock Data

20.33M
48.21M
7.69%
4.93%
3.8%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CHICAGO